We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Allotransplantation of Whole Spleen in Patients With Hepatic Malignant Tumors or Hemophilia A

Eiji Kobayashi, MD, PhD; Michio Miyata, MD, PhD
Arch Surg. 1995;130(6):676-677. doi:10.1001/archsurg.1995.01430060114025.
Text Size: A A A
Published online


We read with interest the report by Liu et al1 in the January issue of the Archives. They performed heterotopic allotransplantation of whole spleen in six patients with hemophilia A or advanced hepatocellular carcinoma. The results showed that the allografted spleen produced coagulating factor VIII and suggested that splenic allotransplantation had a positive effect against unresectable hepatocellular carcinoma. We congratulate the successful cases in the former group based on many scientific works.2

However, the effect of the transplanted spleen on patients with malignant disease is still controversial. From our clinical data on total gastrectomy with splenectomy in patients with advanced gastric cancer and metastatic lymph nodes of the splenic hilum, the positive effect of splenectomy is considered for curative procedures, but its effect on patient prognosis is controversial because no randomized study has been done and there is a lack of knowledge about its mechanism. We are looking


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.